Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | KCNQ2 | O43526 | 16/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23177820 | 0.86 | L3MBTL1 (0.79) | L3MBTL1KCNQ2LMNAMEN1HPGD | |
| SCHEMBL751185 | 0.83 | L3MBTL1 (0.65) | L3MBTL1KCNQ2MEN1HPGDKMT2A | |
| SCHEMBL8369000 | 0.83 | L3MBTL1 (0.60) | L3MBTL1KCNQ2LMNAMEN1HPGD | |
| SCHEMBL23142182 | 0.83 | L3MBTL1 (0.60) | L3MBTL1KCNQ2LMNAMEN1HPGD | |
| SCHEMBL20421907 | 0.82 | L3MBTL1 (0.56) | L3MBTL1KCNQ2LMNAMEN1HPGD | |
| SCHEMBL14263863 | 0.80 | TSHR (0.57) | L3MBTL1LMNAMEN1HPGDKMT2A | |
| SCHEMBL31519821 | 0.80 | L3MBTL1 (0.57) | L3MBTL1KCNQ2MEN1HPGDKMT2A | |
| SCHEMBL3112925 | 0.80 | L3MBTL1 (0.57) | L3MBTL1KCNQ2MEN1HPGDKMT2A | |
| SCHEMBL30795680 | 0.80 | L3MBTL1 (0.57) | L3MBTL1KCNQ2MEN1HPGDKMT2A | |
| SCHEMBL23177713 | 0.79 | L3MBTL1 (0.56) | L3MBTL1KCNQ2MEN1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063044-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2010-03-11 | — | — | US | disclosed |
| US-7601870-B2 | Such as Hexanoic acid (4-bromo-2,6-dimethyl-phenyl)-amide; potassium channel modulators; epilepsy | H. LUNDBECK A/S (DK) | 2009-10-13 | — | — | US | disclosed |
| CN-101056845-A | Substituted aniline derivatives | LUNDBECK & CO AS H (DK) | 2007-10-17 | — | — | CN | disclosed |
| EP-1791809-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2007-06-06 | — | — | EP | disclosed |
| US-20060155121-A1 | Substituted aniline derivatives | H. LUNDBECK A/S (DK) | 2006-07-13 | — | — | US | disclosed |
| WO-2006029623-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063044-A1 | SUBSTITUTED ANILINE DERIVATIVES | NDUFS3, NAT1, PRMT3 | L3MBTL1 1647/4885KCNQ2 332/4885LMNA 1314/4885 |
| US-20060155121-A1 | Substituted aniline derivatives | UGT2B7, NAT1, CYP1A2 | L3MBTL1 3592/4885KCNQ2 2118/4885LMNA 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.